221 related articles for article (PubMed ID: 28589389)
1. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].
Proft F; Schulze-Koops H; Grunke M; Schrezenmeier E; Halleck F; Henes J; Unger L; Schmidt E; Fiehn C; Jacobi A; Iking-Konert C; Kneitz C; Schmidt RE; Bannert B; Voll RE; Fischer-Betz R; Kötter I; Tony HP; Holle J; Aringer M; Erler A; Behrens F; Burmester GR; Dörner T
Z Rheumatol; 2018 Feb; 77(1):28-39. PubMed ID: 28589389
[TBL] [Abstract][Full Text] [Related]
2. [Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)].
Venhoff N; Proft F; Schulze-Koops H; Holle J; Voll RE; Iking-Konert C; Jacobi AM; Henes J; Unger L; Kneitz O; Dörner T; Thiel J
Z Rheumatol; 2018 Feb; 77(1):21-27. PubMed ID: 28508096
[TBL] [Abstract][Full Text] [Related]
3. [Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)].
Henes JC; Schulze-Koops H; Witt M; Tony HP; Mueller F; Grunke M; Czihal M; Dörner T; Proft F
Z Rheumatol; 2018 Feb; 77(1):12-20. PubMed ID: 28536934
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)].
Proft F; Fleck M; Fiehn C; Schulze-Koops H; Witt M; Dörner T; Henes JC
Z Rheumatol; 2018 Feb; 77(1):46-54. PubMed ID: 28589388
[TBL] [Abstract][Full Text] [Related]
5. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).
Witt M; Grunke M; Proft F; Baeuerle M; Aringer M; Burmester G; Chehab G; Fiehn C; Fischer-Betz R; Fleck M; Freivogel K; Haubitz M; Kötter I; Lovric S; Metzler C; Rubberth-Roth A; Schwarting A; Specker C; Tony HP; Unger L; Wassenberg S; Dörner T; Schulze-Koops H;
Lupus; 2013 Oct; 22(11):1142-9. PubMed ID: 24057058
[TBL] [Abstract][Full Text] [Related]
7. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Tony HP; Burmester G; Schulze-Koops H; Grunke M; Henes J; Kötter I; Haas J; Unger L; Lovric S; Haubitz M; Fischer-Betz R; Chehab G; Rubbert-Roth A; Specker C; Weinerth J; Holle J; Müller-Ladner U; König R; Fiehn C; Burgwinkel P; Budde K; Sörensen H; Meurer M; Aringer M; Kieseier B; Erfurt-Berge C; Sticherling M; Veelken R; Ziemann U; Strutz F; von Wussow P; Meier FM; Hunzelmann N; Schmidt E; Bergner R; Schwarting A; Eming R; Hertl M; Stadler R; Schwarz-Eywill M; Wassenberg S; Fleck M; Metzler C; Zettl U; Westphal J; Heitmann S; Herzog AL; Wiendl H; Jakob W; Schmidt E; Freivogel K; Dörner T;
Arthritis Res Ther; 2011 May; 13(3):R75. PubMed ID: 21569519
[TBL] [Abstract][Full Text] [Related]
8. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Mariette X; Gottenberg JE; Ravaud P; Combe B
Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
[TBL] [Abstract][Full Text] [Related]
9. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
Al-Mayouf SM; Alenazi A; AlJasser H
Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
[TBL] [Abstract][Full Text] [Related]
10. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
Díaz-Lagares C; Pérez-Alvarez R; García-Hernández FJ; Ayala-Gutiérrez MM; Callejas JL; Martínez-Berriotxoa A; Rascón J; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Gómez-de-la-Torre R; Sáez L; Canora-Lebrato J; Camps MT; Ortego-Centeno N; Castillo-Palma MJ; Ramos-Casals M;
Arthritis Res Ther; 2011 Jul; 13(4):R112. PubMed ID: 21745378
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
13. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of rituximab for systemic lupus erythematosus in Europe.
Rydén-Aulin M; Boumpas D; Bultink I; Callejas Rubio JL; Caminal-Montero L; Castro A; Colodro Ruiz A; Doria A; Dörner T; Gonzalez-Echavarri C; Gremese E; Houssiau FA; Huizinga T; Inanç M; Isenberg D; Iuliano A; Jacobsen S; Jimenéz-Alonso J; Kovács L; Mariette X; Mosca M; Nived O; Oristrell J; Ramos-Casals M; Rascón J; Ruiz-Irastorza G; Sáez-Comet L; Salvador Cervelló G; Sebastiani GD; Squatrito D; Szücs G; Voskuyl A; van Vollenhoven R
Lupus Sci Med; 2016; 3(1):e000163. PubMed ID: 27651920
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry].
Fiehn C; Unger L; Schulze-Koops H; Proft F; Henes JC; Jacobi A; Dörner T
Z Rheumatol; 2018 Feb; 77(1):40-45. PubMed ID: 28536935
[TBL] [Abstract][Full Text] [Related]
17. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
Roll P; Ostermeier E; Haubitz M; Lovric S; Unger L; Holle J; Kötter I; Henes JC; Bergner R; Rubbert-Roth A; Specker C; Schulze-Koops H; Müller-Ladner U; Fleck M; Burmester GR; Hiepe F; Heitmann S; Aringer M; Fischer-Betz R; Dörner T; Tony HP
J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269
[TBL] [Abstract][Full Text] [Related]
20. Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).
Gottenberg JE; Chaudier A; Allenbach Y; Mekinian A; Amoura Z; Cacoub P; Cornec D; Hachulla E; Quartier P; Melki I; Richez C; Seror R; Terrier B; Devauchelle-Pensec V; Henry J; Gatfosse M; Bouillet L; Gaigneux E; Andre V; Baulier G; Saunier A; Desmurs M; Poulet A; Ete M; Bienvenu B; Truchetet ME; Michaud M; Larroche C; Dellal A; Leurs A; Ottaviani S; Nielly H; Vial G; Jaussaud R; Rouvière B; Jeandel PY; Guffroy A; Korganow AS; Jouvray M; Meyer A; Chatelus E; Sordet C; Felten R; Sibilia J; Litim-Ahmed-Yahia S; Kleinmann JF; Mariette X
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36319066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
